Immune Design is committed to the highest standards of quality in our research and development programs. To this end, we are fortunate to have the support of a world-class board of scientific advisors.
Rafi Ahmed, Ph.D. Chairman
Director, Emory Vaccine Center; Professor of Microbiology and Immunology, Emory University School of MedicineView Bio
Dr. Ahmed studies immunological memory – the ability of the immune system to “remember” a particular antigen and respond accordingly. He and his colleagues have made significant discoveries about how immune memory cells are created and how long they survive; understanding these mechanisms is crucial to the development of vaccines for HIV and other infectious agents. He is an internationally recognized expert on viral persistence and the immune response to viruses. In addition to contributing vitally to vaccine science, Dr. Ahmed’s findings are being applied to research into therapies for the treatment of cancer and the prevention of organ rejection. Dr. Ahmed received his PhD in microbiology from Harvard University. Before to Emory, he was a Professor at the University of California, Los Angeles School of Medicine.
David Baltimore, Ph.D.
Robert A. Millikan Professor of Biology, California Institute of TechnologyView Bio
Dr. Baltimore is co-recipient of the Nobel Prize in Physiology or Medicine for his discovery of reverse transcriptase. He is currently the Robert A. Millikan Professor of Biology at the California Institute of Technology, where he was the president from 1997 to 2006, and the president of the American Association for the Advancement of Science. While at MIT, Baltimore was founding director of the Whitehead Institute. He has had profound influence on national policy concerning recombinant DNA research and the AIDS epidemic. Dr. Baltimore is a member of the Board of Directors of Amgen, Bulletin of the Atomic Scientists Board of Sponsors, Encyclopædia Britannica editorial board, NIH AIDS vaccine task force, and numerous other organizations and their boards. He received a B.A. from Swarthmore College and Ph.D. from The Rockefeller University. He is a member of the National Academy of Sciences and the Institute of Medicine.
Lawrence Corey, M.D.
Past President and Director, Fred Hutchinson Cancer Research Center; Member, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Principal Investigator, HIV Vaccine Trials Network; Professor, Medicine and Laboratory Medicine, University of WashingtonView Bio
Dr. Corey is an internationally renowned expert in virology, immunology and vaccine development, and his research focuses on herpes viruses, HIV and other viral infections, particularly those associated with cancer. He has extensive experience with the development of experimental vaccines for both genital herpes and HIV, and his lab has pioneered novel tests for diagnosing and monitoring therapies for viral infections. His honors and awards include election to the American Academy of Arts and Sciences and to the National Academy of Medicine. He is also the recipient of the American Society for STD Research Parran Award, the University of Michigan Medical School Distinguished Alumnus Award, and the Cubist Award from the American Society of Microbiology. Corey received his bachelor’s and medical degrees from the University of Michigan in Ann Arbor, Michigan, and his infectious diseases training at the University of Washington. He has authored more than 700 scientific publications, 12 books and 150 editorials and book chapters, and has served on numerous editorial boards and national committees.
Philip Greenberg, M.D.
Professor of Medicine & Immunology, University of Washington; Head of Program in Immunology, Fred Hutchinson Cancer Research CenterView Bio
Dr. Greenberg’s laboratory is pursuing studies to elucidate the immunobiology of host immune responses to infectious viruses and transformed cells. He and his colleagues were the first to demonstrate that human antigen-specific T cell clones could be isolated and expanded in vitro and then re-infused into patients to prevent or treat viral infections and to mediate therapeutic responses in patients with cancer. His lab has extensive experience evaluating and modulating T cell responses to tumors and viruses, including introducing genes into T cells to impart specificity and modulate function, designing strategies to overcome tolerance and enhance in vivo activity, and developing mouse models that more accurately model human immune responses to candidate vaccines. He received his bachelor’s degree from Washington University in St. Louis, his MD from SUNY-Downstate summa cum laude, and did post-doctoral studies at UCSD. He was elected to the American Society of Clinical Investigation, American Association of Physicians, Association of American Physicians, American College of Physicians, and the American Association for the Advancement of Science.
Carl H. June, M.D.
Director, Translational Research Program at the Abramson Cancer Center at the University of PennsylvaniaView Bio
Carl June is currently the director of the Translational Research Program at the Abramson Cancer Center at the University of Pennsylvania, and is an Investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with Dr. E. Donnell Thomas and Dr. John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 – 1986. He is board certified in Internal Medicine and Medical Oncology. He founded the Immune Cell Biology Program and was head of the Department of Immunology at the Naval Medical Research Institute from 1990 to 1995. He rose to Professor in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda, Maryland before assuming his current position as a tenured Professor at the University of Pennsylvania in 1999. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy.
Ronald Levy, M.D.
Professor and Chief, Division of Oncology, StanfordView Bio
Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine Associate Director of Translational Science for the Stanford Cancer Institute.
For more than 25 years, Dr. Levy’s research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab (Rituxan®) for the treatment of patients’ lymphomas. Dr. Levy has published over 300 articles in the fields of oncology and immunology. He is using lymphocyte receptors as targets for new therapies for lymphoma, and is currently conducting clinical trials of lymphoma vaccines. In 1982, Dr. Levy he shared the first Armand Hammer Award for Cancer Research, and was later awarded the Ciba Geigy/Drew Award in Biomedical Research, the American Society of Clinical Oncology Karnofsky Award, the General Motors Charles Kettering Prize, the Key to the Cure Award by the Cure for Lymphoma Foundation, the Medal of Honor by the American Cancer Society, the Evelyn Hoffman Memorial Award by the Lymphoma Research Foundation of America, the 2004 Damashek Prize from the American Society of Hematology and in 2009 he was elected to the National Academy of Sciences and he won the King Faisal International Prize in Medicine.
Steven Reed, Ph.D.
Infectious Disease Research InstituteView Bio
Steve Reed founded Immune Design Corp. in 2008 and served as the Chief Executive Officer through May 2011. He is the founder, President and Chief Scientific Officer of the Infectious Disease Research Institute. He co-founded Corixa Corporation in 1994, where he served as Chief Scientific Officer. In 2005 he founded Dharma Therapeutics Inc., a Seattle biotech developing transdermal delivery systems. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health and is a member of the Vaccine Development Steering Committee of the World Health Organization. Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of adjuvants, vaccines and diagnostics for both cancer and infectious diseases. He has more than 210 published original articles, several book chapters, and holds 101 issued patents for diagnostics, vaccines, and therapeutics for infectious diseases and cancer.
Inder Verma, Ph.D.
Professor, Laboratory of Genetics; American Cancer Society Professor of Molecular Biology, Salk Institute, La JollaView Bio
Dr. Verma is one of the world’s leading authorities on the development and use of engineered viruses for gene therapy. Dr. Verma and colleagues developed a gene therapy vector, based on a stripped-down version of HIV, that can deliver genes to non-dividing cells. In addition to gene therapy technologies, Dr Verma’s major research interests are cellular genes whose alteration can cause or suppress cancer. Dr. Verma received a master’s degree from Lucknow University, and a Ph.D. from The Weizmann Institute of Science in Rehovoth, Israel. After postdoctoral study at MIT in the laboratory of the Nobel laureate David Baltimore, he joined the faculty of The Salk Institute. For his many outstanding accomplishments, Dr. Verma was elected to the U.S. National Academy of Sciences and as a Foreign Fellow to the National Academy of Sciences, India. Dr. Verma was also elected to the Third World Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the American Philosophical Society.